Drug Search Results
More Filters [+]

Eluxadoline

Alternative Names: eluxadoline, jnj-27018966, Viberzi
Latest Update: 2023-12-22
Latest Update Note: Clinical Trial Update

Product Description

Eluxadoline is a new therapeutic agent that reduced symptoms of IBS with diarrhea in men and women, with sustained efficacy over 6 months in patients who received the 100-mg dose twice daily. a new oral agent with mixed opioid effects (μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist) (Sourced from: https://www.nejm.org/doi/full/10.1056/nejmoa1505180)

Mechanisms of Action: OPRD Antagonist,OPRK Agonist,OPRM Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Belgium | Canada | European Medicines Agency | Hungary | Ireland | Italy | Latvia | Lithuania | New Zealand | Poland | Portugal | Saudi Arabia | Spain | Sweden | United Kingdom | United States

Approved Indications: Irritable Bowel Syndrome | Diarrhea

Known Adverse Events: Abdominal Pain | Pain Unspecified | Constipation

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eluxadoline

Countries in Clinic: Bulgaria, Canada, Hungary, Netherlands, Poland, United Kingdom, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Diarrhea|Irritable Bowel Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT04880876

P3

Enrolling by invitation

Irritable Bowel Syndrome|Diarrhea

2027-03-15

41%

NCT03339128

P2

Recruiting

Irritable Bowel Syndrome|Diarrhea

2026-12-15

Recent News Events